Revisiting the molecular epidemiology of factor XI deficiency: Nine new mutations and an original large 4qTer deletion in western Brittany (France)

Summary

Constitutional deficiency in factor XI (FXI) is a rare bleeding disorder in the general population, with the exception of Ashkenazi Jews. During the last decade, the detection of FXI-deficient patients has shifted from clinical screening identifying mostly severe bleeders to biological screening combining findings of prolonged activated partial thromboplastin time and FXI coagulation activity (FXI:C) below 50 U/dl. The goal of this study was to determine the molecular basis of FXI deficiency in western Brittany, France. Over the course of four years, we detected 98 FXI-deficient patients through biological screening, and 44 patients agreed to participate in this study corresponding to 25 index cases. We developed an efficient mutation detection strategy (combining direct sequencing and QFM-PCR to search for heterozygous rearrangements in a routine setting) that detected F11 mutations in 24 out of the 25 index cases. An unexpected allelic heterogeneity was found, with 14 different single point mutations being detected, among which nine are new. Moreover, a large heterozygous deletion of the entire F11 gene was detected, and was then further defined using a CGH array as a 4q34.2 telomeric deletion of 7 Mb containing 77 genes. We propose that the observed recurrent mutations may be considered as genetic tags of a population. This study highlights the importance of screening for large deletions in molecular studies of F11.

Keywords

Factor XI deficiency - genetic analysis - mutation - deletion - F11 gene

• References

• 1 Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood 2010; 115: 2569-2577.
• 2 McMullen BA, Fujikawa K, Davie EW. Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry 1991; 30: 2056-2060.
• 3 van der Graaf F, Greengard JS, Bouma BN. et al. Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem 1983; 258: 9669-9675.
• 4 Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia 2008; 14: 1183-1189.
• 5 Saunders RE, Shiltagh N, Gomez K. et al. Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency. Thromb Haemost 2009; 102: 287-301.
• 6 Saunders RE, O’Connell NM, Lee CA. et al. Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Hum Mutat 2005; 26: 192-198.
• 7 Asakai R, Davie EW, Chung DW. Organization of the gene for human factor XI. Biochemistry 1987; 26: 7221-7228.
• 8 Shpilberg O, Peretz H, Zivelin A. et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85: 429-432.
• 9 Asakai R, Chung DW, Davie EW. et al. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325: 153-158.
• 10 Hancock JF, Wieland K, Pugh RE. et al. A molecular genetic study of factor XI deficiency. Blood 1991; 77: 1942-1948.
• 11 Quélin F, Trossaërt M, Sigaud M. et al. Molecular basis of severe factor XI deficiency in seven families from the west of France. Seven novel mutations, including an ancient Q88X mutation. J Thromb Haemost 2004; 02: 71-76.
• 12 Zivelin A, Bauduer F, Ducout L. et al. Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood 2002; 99: 2448-2454.
• 13 Mitchell M, Dai L, Savidge G. et al. An Alu-mediated 31.5-kb deletion as the cause of factor XI deficiency in 2 unrelated patients. Blood 2004; 104: 2394-2396.
• 14 Zucker M, Zivelin A, Landau M. et al. Characterization of seven novel mutations causing factor XI deficiency. Haematologica 2007; 92: 1375-1380.
• 15 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
• 16 Mitchell M, Mountford R, Butler R. et al. Spectrum of factor XI (F11) mutations in the UK population--116 index cases and 140 mutations. Hum Mutat 2006; 27: 829.
• 17 Le Maréchal C, Masson E, Chen J-M. et al. Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat Genet 2006; 38: 1372-1374.
• 18 Fard-Esfahani P, Lari GR, Ravanbod S. et al. Seven novel point mutations in the F11 gene in Iranian FXI-deficient patients. Haemophilia 2008; 14: 91-95.
• 19 Seligsohn U. Factor XI deficiency in humans. J. Thromb Haemost 2009; 07 (01) 84-87.
• 20 Quélin F, Mathonnet F, Potentini-Esnault C. et al. Identification of five novel mutations in the factor XI gene (F11) of patients with factor XI deficiency. Blood Coagul Fibrinolysis 2006; 17: 69-73.
• 21 Richard C, Pennarun E, Kivisild T. et al. An mtDNA perspective of French genetic variation. Ann Hum Biol 2007; 34: 68-79.
• 22 Hill M, McLeod F, Franks H. et al. Genetic analysis in FXI deficiency: six novel mutations and the use of a polymerase chain reaction-based test to define a whole gene deletion. Br J Haematol 2005; 129: 825-829.
• 23 Tsai CH, Van Dyke DL, Feldman GL. Child with velocardiofacial syndrome and del (4)(q34.2): another critical region associated with a velocardiofacial syndrome-like phenotype. Am J Med Genet 1999; 82: 336-339.
• 24 Tupler R, Berardinelli A, Barbierato L. et al. Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. J Med Genet 1996; 33: 366-370.
• 25 Kitsiou-Tzeli S, Sismani C, Koumbaris G. et al. Distal del(4) (q33) syndrome: detailed clinical presentation and molecular description with array-CGH. Eur J Med Genet 2008; 51: 61-67.
• 26 Pickard BS, Hollox EJ, Malloy MP. et al. A 4q35.2 subtelomeric deletion identified in a screen of patients with co-morbid psychiatric illness and mental retardation. BMC Med. Genet 2004; 05: 21.